Triple targeting host-guest drug delivery system based on lactose-modified azocalixarene for tumor ablation
Li, JJ (Li, Juan-Juan)  ; Rong, RX (Rong, Rui-Xue)  ; Yang, Y (Yang, Yan)  ; Hu, ZY (Hu, Zong-Ying)  ; Hu, B (Hu, Bing)  ; Zhao, YY (Zhao, Ying-Ying)  ; Li, HB (Li, Hua-Bin)  ; Hu, XY (Hu, Xin-Yue)  ; Wang, KR (Wang, Ke-Rang)  ; Guo, DS (Guo, Dong-Sheng) 
Article; Early Access
Host-guest drug delivery systems (HGDDSs) have been studied in an effort to modify the characteristics of therapeutic agents through noncovalent interactions, reduce toxic side effects and improve therapeutic effects. However, it is still an important task to continuously improve the targeting ability of HGDDSs, which is conducive to the development of precision medicine. Herein, we utilize the lactose-modified azocalixarene (LacAC4A) as a triple targeting drug carrier customized for antitumor purposes. LacAC4A integrates three targeting features, passive targeting through the enhancing permeability and retention effect, active targeting by the interactions of lactose and the asialoglycoprotein receptors on the surface of tumor cells, and stimuli-responsive targeting via the reduction of the azo group under a hypoxia microenvironment. After loading doxorubicin (DOX) in LacAC4A, the supramolecular nanoformulation DOX@LacAC4A clearly showed the effective suppression of tumor growth through in vivo experiments. LacAC4A can achieve effective targeting, rapid release, and improve drug bioavailability. This design principle will provide a new material for drug delivery systems.